 |
Myeloma Canada Welcomes Gabriele Colasurdo to the Management Team
Myeloma Canada is pleased to
welcome Gabriele Colasurdo to the team as Manager of Education and Patient Services. In his role, Gabriele will
plan, develop and implement Myeloma Canada's portfolio of educational resources, disease awareness programs and scientific meetings.
Gabriele graduated from Concordia University in Montreal with a Masters of Science in Biochemistry. His experience includes medical writing, developing accredited continuing medical education programs and guiding the creation of scientific content for meetings. Fluent in three languages (English, French, and Italian), Gabriele also enjoys
playing hockey and traveling in his free time.
We warmly welcome Gabriele to the Myeloma Canada team! Gabriele can be reached at [email protected]
|
The Myeloma Canada Webinar is Now Available on YouTube
The Drug Approval Process in Canada, and How You Can Help Accelerate Access
 |
|
|
Click on image to view recording
|
In case you didn't have a chance to participate in Myeloma Canada's Webinar, "The Drug Approval Process in Canada and How You Can Help Accelerate Access", the Webinar was recorded and is available for viewing at any time on YouTube.
You can access recordings and videos can be accessed via the Myeloma Canada website at www.myeloma.ca
under the 'Resources' tab.
If you require any additional information on this topic or would like to ask a question, you can contact Martine Elias directly at
[email protected].
|
Myeloma Canada is Pleased to Announce Revlimid® (lenalidomide) as First-line Treatment for Non-Transplant Eligible Myeloma Patients Now Funded in Ontario and British Columbia
Read more...
|
NEW! The Myeloma Canada Kidney InfoGuide is Now Available Online and in Print
Myeloma and the Kidney InfoGuide
This InfoGuide is written for patients with myeloma, their families and friends. It explains the role of the kidneys, why and how myeloma may affect the kidneys, the symptoms of kidney disease and how it is diagnosed and managed.
|
|
|
|
Brenda and Dan Wigle
|
Spotlight on the Myeloma Community
A Caregiver's Story
Meet Brenda Wigle, wife and caregiver of a myeloma patient since 2011.
"I am occasionally reminded: It is what it is, you do what you can do, life it to be lived and on good days, go like hell."
|
MCRN Canadian-Designed Clinical Trial Inspires a Global Phase III Trial
Inspired by the success of the Phase II MCRN 002 STOMP trial, Karyopharm has turned to
MCRN investigators to participate and lead the Phase III global registration trial for selinexor.
|
From InfoSessions to fundraisers and events, find out what's happening in our community.
Pictured left: Terrilyn (caregiver) and Ron Surry (patient and Support Group Leader) speaking about their experiences of living with myeloma at the Kelowna InfoSession.
|
|
Myeloma Canada and Advocacy
Although the prevalence of myeloma in Canada is increasing, myeloma remains a relatively unknown disease, often resulting in delayed diagnosis and limited funding and reimbursement for new therapies.
To put this in perspective, several game-changing therapies were approved by Health Canada in 2016, yet none of them are reimbursed by our provinces. These include:
- Kyprolis® (carfilzomib)
- Darzalex® (daratumumab)
- Ninalro® (ixazomib)
- Empliciti® (elotuzumab)
To learn more, view Myeloma Canada's recent Educational Webinar on "The Drug Approval Process in Canada and How You Can Help Accelerate Access", click
HERE.
Myeloma Advocacy Program:
MAP
Myeloma Canada's role is to empower patients to have their voices heard. Sharing your story is key to influence and shape reimbursement decisions of new myeloma treatments. We are pleased to unveil Myeloma Canada's M.A.P. (Myeloma Advocacy Program).
Myeloma Canada has developed an easy tool for you to help advocate for access to new treatments by writing your local MPP/MLA/MNA and urging them to act.
Access to new treatments is vital fo
r patients. Thousands of Canadians depend on it. Do your part, and help make a difference.
By Participating in the MAP, you will put myeloma on the map.
Click here to take action
|
Welcome to Myeloma Canada's New Office
Our team is pleased to welcome the community to our new office now located at :
1255 Trans Canada Hwy, Suite 160
Dorval, QC
H9P 2V4
Please note our phone number has changed to:
514.421.2242
Our toll-free number and email address have remained unchanged:
|
Donate or Register for the 2017 Multiple Myeloma March
The Multiple Myeloma March is the only annual large-scale
fundraiser that exclusively
supports the
Canadian myeloma community.
Each year in September, communities
across the country rally for a
5km walk
to increase
awareness and raise
funds for clinical research and to support advocacy, for accelerated access to game-changing therapies for Canadians. To register or to donate, visit:
|
|
See what's happening on the social sites of Myeloma Canada:
|
|
| |
|
|
|
|
